Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Poor countries desperately need better access to generic medicines

As the Access to Medicine Foundation publishes the first ever analytical framework specifically for generic and biosimilar medicine manufacturers, Jayasree Iyer, CEO, writes for the Financial Times about why this is important.

Date

15 February 2023

Direct links

Read the article

The piece describes the opportunities that are available to generics companies and the need for them to make a conscious effort to address global health challenges and realise their potential as key players in access to medicine.

"We know this is possible, because generics companies are already experts at delivering lower-cost treatments at scale, and have stepped up previously to address urgent issues."

Read the article on the Financial Times website.

Download the framework

The Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved